EPO and neoplasm: We also found a significant increase in tumor volume in Ht-29 xenografts treated with Epo compared with DLD-1 xenografts receiving Epo (p < 0.05) as well as tumor volume in the second week in these groups (p < 0.05) (Fig. 7).